2 A new name you might hear about is retatrutide, but its important to know this medication is still experimental
But the pricing landscape is shifting fast in 2026, with new oral options, a landmark Medicare program, and negotiated prices on the horizon
These companies generated tens of billions in revenue from these medications while allegedly downplaying severe adverse effects that went far beyond the bloating , constipation , and nausea listed on standard warning labels
Now, the primary audience is often the P&T committee and the PBMs financial negotiators
How Marketing Exploits Scientific Language Cherry-picking studies: Marketing materials cite research demonstrating GLP-1 increases while omitting discussion of effect sizes, duration, or clinical outcomes